{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T15:47:31Z","timestamp":1760888851955},"reference-count":28,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.3892\/br.2013.145","type":"journal-article","created":{"date-parts":[[2013,7,22]],"date-time":"2013-07-22T10:23:48Z","timestamp":1374488628000},"page":"719-722","source":"Crossref","is-referenced-by-count":13,"title":["Investigation of inhibitory effects on EPC-mediated neovascularization by different bisphosphonates for cancer therapy"],"prefix":"10.3892","volume":"1","author":[{"given":"THOMAS","family":"ZIEBART","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JOHANNA","family":"ZIEBART","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LEONIE","family":"GAUSS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ANDREAS","family":"PABST","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MAXIMILIAN","family":"ACKERMANN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RALF","family":"SMEETS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MORITZ A.","family":"KONERDING","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHRISTIAN","family":"WALTER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2013,7,22]]},"reference":[{"key":"key20180107142417_b1-br-01-05-0719","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.ejca.2010.02.041","article-title":"Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease","volume":"46","author":"Neville-Webbe","year":"2010","journal-title":"Eur J Cancer"},{"key":"key20180107142417_b2-br-01-05-0719","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"key20180107142417_b3-br-01-05-0719","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.2174\/1381612033453640","article-title":"New insights into the molecular mechanisms of action of bisphosphonates","volume":"9","author":"Rogers","year":"2003","journal-title":"Curr Pharm Des"},{"key":"key20180107142417_b4-br-01-05-0719","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"key":"key20180107142417_b5-br-01-05-0719","first-page":"235","article-title":"Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"key20180107142417_b6-br-01-05-0719","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1073\/pnas.96.1.133","article-title":"Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro","volume":"96","author":"Fisher","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107142417_b7-br-01-05-0719","first-page":"1080","article-title":"Pamidronate induces modifications of circulating angiogenetic factors in cancer patients","volume":"8","author":"Santini","year":"2002","journal-title":"Clin Cancer Res"},{"key":"key20180107142417_b8-br-01-05-0719","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jss.2008.01.031","article-title":"Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation","volume":"151","author":"Yamada","year":"2009","journal-title":"J Surg Res"},{"key":"key20180107142417_b9-br-01-05-0719","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00784-009-0365-2","article-title":"Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro","volume":"15","author":"Ziebart","year":"2011","journal-title":"Clin Oral Investig"},{"key":"key20180107142417_b10-br-01-05-0719","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","article-title":"Tumor angiogenesis","volume":"358","author":"Kerbel","year":"2008","journal-title":"N Engl J Med"},{"key":"key20180107142417_b11-br-01-05-0719","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00001813-199502000-00001","article-title":"Consequences of angiogenesis for tumor progression, metastasis and cancer therapy","volume":"6","author":"Rak","year":"1995","journal-title":"Anticancer Drugs"},{"key":"key20180107142417_b12-br-01-05-0719","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1161\/01.RES.85.3.221","article-title":"Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization","volume":"85","author":"Asahara","year":"1999","journal-title":"Circ Res"},{"key":"key20180107142417_b13-br-01-05-0719","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1126\/science.275.5302.964","article-title":"Isolation of putative progenitor endothelial cells for angiogenesis","volume":"275","author":"Asahara","year":"1997","journal-title":"Science"},{"key":"key20180107142417_b14-br-01-05-0719","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1161\/CIRCRESAHA.108.180463","article-title":"Sustained persistence of transplanted proangiogenic cells contributes to neovascularization and cardiac function after ischemia","volume":"103","author":"Ziebart","year":"2008","journal-title":"Circ Res"},{"key":"key20180107142417_b15-br-01-05-0719","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nm1182","article-title":"Cathepsin L is required for endothelial progenitor cell-induced neovascularization","volume":"11","author":"Urbich","year":"2005","journal-title":"Nat Med"},{"key":"key20180107142417_b16-br-01-05-0719","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.urology.2004.08.041","article-title":"Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment","volume":"65","author":"Efstathiou","year":"2005","journal-title":"Urology"},{"key":"key20180107142417_b17-br-01-05-0719","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s00280-005-0025-4","article-title":"Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients","volume":"57","author":"Bertelli","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20180107142417_b18-br-01-05-0719","first-page":"1109","article-title":"Breast tumour growth inhibition in vitro through the combination of cyclophosphamide\/metotrexate\/5-fluorouracil, epirubicin\/cyclophosphamide, epirubicin\/paclitaxel, and epirubicin\/docetaxel with the bisphosphonates ibandronate and zoledronic acid","volume":"12","author":"Vogt","year":"2004","journal-title":"Oncol Rep"},{"key":"key20180107142417_b19-br-01-05-0719","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"key20180107142417_b20-br-01-05-0719","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1100\/tsw.2010.100","article-title":"The role and therapeutic potential of endothelial progenitor cells in tumor neovascularization","volume":"10","author":"Janic","year":"2010","journal-title":"Sci World J"},{"key":"key20180107142417_b21-br-01-05-0719","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2003-12-4423","article-title":"SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells","volume":"104","author":"De Falco","year":"2004","journal-title":"Blood"},{"key":"key20180107142417_b22-br-01-05-0719","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/jso.21139","article-title":"Elevated levels of circulating endothelial progenitor cells in head and neck cancer patients","volume":"98","author":"Brunner","year":"2008","journal-title":"J Surg Oncol"},{"key":"key20180107142417_b23-br-01-05-0719","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1161\/01.HYP.0000154789.28695.ea","article-title":"Mobilizing endothelial progenitor cells","volume":"45","author":"Aicher","year":"2005","journal-title":"Hypertension"},{"key":"key20180107142417_b24-br-01-05-0719","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/01.ATV.0000073832.49290.B5","article-title":"Endothelial progenitor cells: mobilization, differentiation, and homing","volume":"23","author":"Hristov","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key20180107142417_b25-br-01-05-0719","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1359\/jbmr.1997.12.9.1358","article-title":"Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5\u2032-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro","volume":"12","author":"Frith","year":"1997","journal-title":"J Bone Miner Res"},{"key":"key20180107142417_b26-br-01-05-0719","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3727\/096504005775082093","article-title":"Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells","volume":"15","author":"Nogawa","year":"2005","journal-title":"Oncol Res"},{"key":"key20180107142417_b27-br-01-05-0719","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.lfs.2005.05.017","article-title":"Role of the isoprenoid pathway in ras transforming activity, cytoskeleton organization, cell proliferation and apoptosis","volume":"77","author":"Bifulco","year":"2005","journal-title":"Life Sci"},{"key":"key20180107142417_b28-br-01-05-0719","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1006\/bbrc.1997.7145","article-title":"Novel salvage pathway utilizing farnesol and geranylgeraniol for protein isoprenylation","volume":"237","author":"Crick","year":"1997","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Biomedical Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/br.2013.145\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T14:43:30Z","timestamp":1515336210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/br.2013.145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,22]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,7,22]]},"published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.3892\/br.2013.145"],"URL":"https:\/\/doi.org\/10.3892\/br.2013.145","relation":{},"ISSN":["2049-9434","2049-9442"],"issn-type":[{"value":"2049-9434","type":"print"},{"value":"2049-9442","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,22]]}}}